PSMA-targeted [ 18 F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework

Research output: Contribution to journalArticle

Abstract

We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment planning. Notably, the presented patient was found to have an equivocal bone lesion (PSMA-RADS-3B) which was further worked up with a tumor protocol MRI and found to be definitively benign (PSMA-RADS-1B) and thus removed from the oligometastatic treatment plan. Remaining avid lesions were incorporated into the treatment plan or deferred for later work-up or monitoring, as indicated within the PSMA-RADS framework.

Original languageEnglish (US)
Pages (from-to)72-74
Number of pages3
JournalUrology Case Reports
Volume23
DOIs
StatePublished - Mar 2019

Keywords

  • DCFPyL
  • Oligometastatic
  • PSMA
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'PSMA-targeted [ <sup>18</sup> F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework'. Together they form a unique fingerprint.

  • Cite this